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Dear editor
We have read with interest the recently published comparative study regarding the 
accelerated versus conventional corneal collagen cross-linking (CXL) in the treatment 
of mild keratoconus. We would like to underline the importance of the CXL treatment 
time reduction in this time consuming operation.1 Accelerated CXL became popular 
due to patient and doctor comfort in comparison to the previously widespread use of 
Dresden protocol which is successful in terms of safety and efficacy. Based on the 
Bunsen-Roscoe law of reciprocity many modifications to the time and irradiation set-
tings have been proposed while the total energy dose delivered to the cornea should 
be maintained at 5.4 J/cm2.2
We already proved, by measuring (with the use of anterior segment optical 
coherence tomography) the demarcation line depth at 1 month postoperatively after 
CXL, that the treatment depth was significantly different (significantly shallower in 
accelerated protocol) between the 10 minute accelerated protocol with ultraviolet-A 
(UV-A) irradiation intensity of 9 mW/cm2 and the 30 minute standard Dresden pro-
tocol with UV-A of 3 mW/cm2.2 Our results suggested that Bunsen-Roscoe law of 
reciprocity may not directly apply to CXL in living cornea tissue, thus, an increased 
total energy dose should probably be applied to the keratoconic cornea in order 
to achieve a treatment effect comparable to the already proven effective standard 
Dresden CXL protocol.
Consequently, we have proceeded with relevant modifications for the UV-A time set-
tings of the currently proposed accelerated CXL protocol (10 minutes) by increasing the 
UV-A irradiation time to 14 minutes (40% increase) and we achieved a treatment effect 
comparable with the Dresden protocol (as indicated by the demarcation line depth).3
In the recently published article by Sherif, it is presumed that the accelerated group 
of patients received CXL treatment according to Bunsen-Roscoe law which should 
have been 3 minutes of UV-A with irradiation intensity of 30 mW/cm2 corresponding 
to 5.4 J/cm2 total energy dose delivered to the cornea.1 Interestingly, Sherif mentioned 
that the accelerated group received UV-A treatment with 30 mW/cm2 for 4 minutes 
and 20 seconds; thus the accelerated group received about 40% more UV-A irradiation 
time, which is comparable to our time setting modifications (from 10 to 14 minutes). 
Moreover it should be clarified whether the author modified the time settings manu-
ally or if these modifications were made according to the UV-A device manufacturer’s 
instructions (Avedro, Inc., Waltham, MA, USA). In addition we would like to enquire 
whether the author performed measurements (eg, endothelial cell density) concerning 
the safety of the time and irradiation intensity settings used in this study.4
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As we previously published, an indirect and non-contact 
method to measure the effectiveness of CXL treatment is 
the demarcation line depth provided with anterior segment 
optical coherence tomography; our results were the same 
with the reliable but more invasive (due to contact with the 
treated cornea) confocal microscopy.5 Thus, measurement of 
the demarcation line depth at 1 month postoperatively could 
provide useful information in suggesting modifications to any 
of the CXL treatment settings.6 It should be of great interest 
whether the author could provide such measurement results 
concerning the studied groups of this article. Moreover, we 
should bring to the attention that in cases of mild keratoconus 
it should probably need a longer follow-up period to establish 
reliable results concerning the effectiveness of treatment in 
arresting keratoconus progression.
In conclusion we believe that accelerated CXL treatment 
settings in agreement to Bunsen-Roscoe law of reciprocity 
should be revised thoroughly and new modifications have 
to be carefully made regarding time and irradiation intensity 
adjustments keeping the safety aspect of CXL treatment as 
the first priority.
Disclosure
The authors report no conflicts of interest in this commu-
nication.
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Dear editor
I read the valuable comments of Dr Kymionis and 
Dr Tsoulnaras
Regarding the question relating to the duration of the 
accelerated cross-linking (CXL), duration was set accord-
ing to the manufacturer (Avedro, Inc., Waltham, MA, USA) 
recommendations. The author agrees that Bunsen-Roscoe 
law of reciprocity may not directly apply for CXL in living 
cornea tissue as proved by Dr Kymionis et al.1
Regarding the question whether the author performed 
endothelial cell density (ECD): ECD was not performed 
in the study group but there are several recent publications 
that evaluated the ECD after accelerated corneal collagen 
cross-linking.2–4 The author is currently conducting a study 
evaluating different ultra violet-A settings where ECD is 
among the evaluation criteria. The results will be published 
in the coming months.
The author agrees with Dr  Kymionis and Dr Tsoulnaras 
that modifications  in ultra violet-A settings have to be care-
fully made regarding time and irradiation intensity keeping 
the safety aspect of CXL treatment as the first priority.
Disclosure
The author reports no conflicts of interest in the communica-
tion.
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